A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics
Principal Investigator (?)
The purpose of this study is to further evaluate the safety of infliximab and ustekinumab in patients with plaque psoriasis, and other all forms of psoriasis (such as plaque psoriasis and psoriatic arthritis occurring together). The registry study will track the behavior of the disease in response to other therapies, such as other biologic drugs. The registry will also evaluate clinical outcomes; disease characteristics, including physician reported assessment of psoriatic arthritis (PsA); quality of life, and potential risks for patients who may receive standard therapies for psoriasis.
Centocor Ortho Biotech Services, LLC.
Available at the following location(s)
- Decision-Making Help
- Medical Records & Release Forms
- Health Encyclopedia
- Clinical Trials
- Lifestyle Changes
- Emmi® Patient Education
- Frequently Asked Questions on Scabies